Vivoryon Therapeutics N.V. (AMS:VVY)
Netherlands
· Delayed Price · Currency is EUR 1.290
-0.010 (-0.77%)
Apr 28, 2026, 5:35 PM CET
Vivoryon Therapeutics Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | - | - | -3.62 | - | 10.76 | Upgrade
|
| Cost of Revenue | - | - | -0.53 | - | 1.57 | Upgrade
|
| Gross Profit | - | - | -3.1 | - | 9.2 | Upgrade
|
| Selling, General & Admin | 4.8 | 6.9 | 8.6 | 8.91 | 4.55 | Upgrade
|
| Research & Development | 4.38 | 14.06 | 17.64 | 20.22 | 17.45 | Upgrade
|
| Other Operating Expenses | -0.27 | - | -0.5 | -0.02 | -0.01 | Upgrade
|
| Operating Expenses | 8.91 | 20.96 | 25.74 | 29.11 | 21.99 | Upgrade
|
| Operating Income | -8.91 | -20.96 | -28.84 | -29.11 | -12.8 | Upgrade
|
| Interest Expense | -0.05 | -0.05 | -0.06 | -0.02 | -0.02 | Upgrade
|
| Interest & Investment Income | 0.11 | 0.43 | 0.48 | 0.04 | 0.02 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.02 | -0.2 | 0.69 | 0.75 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | 0.05 | -0.1 | Upgrade
|
| EBT Excluding Unusual Items | -8.85 | -20.57 | -28.62 | -28.35 | -12.15 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 0.04 | -0.01 | -0.08 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0 | - | - | - | Upgrade
|
| Pretax Income | -8.85 | -20.57 | -28.58 | -28.36 | -12.22 | Upgrade
|
| Income Tax Expense | - | - | -0.23 | -0.2 | 0.43 | Upgrade
|
| Net Income | -8.85 | -20.57 | -28.34 | -28.16 | -12.66 | Upgrade
|
| Net Income to Common | -8.85 | -20.57 | -28.34 | -28.16 | -12.66 | Upgrade
|
| Shares Outstanding (Basic) | 27 | 26 | 25 | 22 | 20 | Upgrade
|
| Shares Outstanding (Diluted) | 27 | 26 | 25 | 22 | 20 | Upgrade
|
| Shares Change (YoY) | 2.92% | 3.27% | 14.64% | 10.10% | 0.12% | Upgrade
|
| EPS (Basic) | -0.33 | -0.79 | -1.12 | -1.28 | -0.63 | Upgrade
|
| EPS (Diluted) | -0.33 | -0.79 | -1.12 | -1.28 | -0.63 | Upgrade
|
| Free Cash Flow | -8.46 | -19.18 | -21.56 | -21.81 | -11.28 | Upgrade
|
| Free Cash Flow Per Share | -0.32 | -0.74 | -0.85 | -0.99 | -0.56 | Upgrade
|
| Gross Margin | - | - | - | - | 85.42% | Upgrade
|
| Operating Margin | - | - | - | - | -118.91% | Upgrade
|
| Profit Margin | - | - | - | - | -117.57% | Upgrade
|
| Free Cash Flow Margin | - | - | - | - | -104.77% | Upgrade
|
| EBITDA | -8.77 | -20.87 | -28.76 | -29.04 | -12.73 | Upgrade
|
| EBITDA Margin | - | - | - | - | -118.22% | Upgrade
|
| D&A For EBITDA | 0.15 | 0.09 | 0.08 | 0.07 | 0.07 | Upgrade
|
| EBIT | -8.91 | -20.96 | -28.84 | -29.11 | -12.8 | Upgrade
|
| EBIT Margin | - | - | - | - | -118.91% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.